China's emergency approval of Pfizer's new crown oral drug: indications, contraindications, clinical trials

In stark contrast to the delay in approving the mRNA vaccine BNT162b jointly developed by Pfizer/BioNTech, the State Drug Administration of China issued an emergency conditional approval on February 11 for Pfizer's Covid-19 prescription drug naimatevir/ritonavir (nirmatrelvir/ritonavir) tablets (trade name Paxlovid), at this time only 50 days have passed since the U.
S.
Food and Drug Administration (FDA) granted the drug an emergency use authorization (EUA) on December 22 last year
.

This means that as long as the output is allowed and the price is reasonable, the drug can enter Chinese hospitals and pharmacies at any time, as a supplement to various new crown drugs being developed or approved in China, in order to protect people's health, open the country in an orderly manner, and appropriately adjust epidemic prevention policies Provide a solid foundation
.

Based on the relevant content of NEJM Journal Watch and FDA's official website, we have sorted out the mechanism of action, usage and dosage, indications, contraindications and clinical trial data of Paxlovid for readers that have not been formally published after peer review.
Clinician's reference, does not constitute any medical advice
.

Learn more, please